# HUTCHMED (China) Ltd: overview HCM · Nasdaq · CIK 1648257 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/hcm.md) · [Financials](/companies/hcm/financials.md) · [Filings](/companies/hcm/filings.md) · [Insiders](/companies/hcm/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [356](/filings/0001104659-24-028454.md) | [426](/filings/0001410578-25-000377.md) | [838](/filings/0001104659-26-023822.md) | [630](/filings/0001104659-26-023822.md) | [549](/filings/0001104659-26-023822.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(92.2%)](/filings/0001104659-24-028454.md) | [(95.6%)](/filings/0001410578-25-000377.md) | [2.2%](/filings/0001104659-26-023822.md) | [(6.9%)](/filings/0001104659-26-023822.md) | [(7.1%)](/filings/0001104659-26-023822.md) | | Net margin | % | [(54.7%)](/filings/0001104659-24-028454.md) | [(84.6%)](/filings/0001410578-25-000377.md) | [12.0%](/filings/0001104659-26-023822.md) | [6.0%](/filings/0001104659-26-023822.md) | [83.3%](/filings/0001104659-26-023822.md) | | Diluted EPS | $ per share | [(0.25)](/filings/0001104659-24-028454.md) | [(0.43)](/filings/0001410578-25-000377.md) | [0.12](/filings/0001104659-26-023822.md) | [0.04](/filings/0001104659-26-023822.md) | [0.52](/filings/0001104659-26-023822.md) | | Free cash flow | $m | [(221)](/filings/0001104659-24-028454.md) | [(305)](/filings/0001410578-25-000377.md) | [187](/filings/0001104659-26-023822.md) | [(17.4)](/filings/0001104659-26-023822.md) | [(78.8)](/filings/0001104659-26-023822.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hcm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SCHRODER INVESTMENT MANAGEMENT GROUP](/funds/1086619.md) | 2026-06-30 | $15.8m | 1,477,494 | | Unchanged | | [Allianz Asset Management GmbH](/funds/1535323.md) | 2026-06-30 | $12.5m | 837,475 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.4m | 313,611 | | Added +8,782 | | [AIA Group Ltd](/funds/1522877.md) | 2026-06-30 | $3.1m | 291,229 | | Unchanged | | [M&G PLC](/funds/1802539.md) | 2026-06-30 | $2.7m | 242,791 | | Reduced −12,677 | | [Amundi](/funds/1330387.md) | 2026-06-30 | $2.2m | 204,385 | | Reduced −27,861 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.1m | 194,472 | | Added +117,958 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.4m | 130,200 | | Reduced −1,862 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $1.1m | 104,425 | | Reduced −2,079 | | [XY Capital Ltd](/funds/1933132.md) | 2026-06-30 | $1.1m | 104,130 | | Added +55,736 | ## Recent filings [All 609 filings](/companies/hcm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 06:08 ET | [6-K](/filings/0001648257-26-000072.md) | Report of a foreign private issuer, period 2026-10-29 | 0001648257-26-000072 | | 2026-10-27 | 06:08 ET | [6-K](/filings/0001648257-26-000070.md) | Report of a foreign private issuer, period 2026-10-27 | 0001648257-26-000070 | | 2026-10-26 | 06:22 ET | [6-K](/filings/0001648257-26-000068.md) | Report of a foreign private issuer, period 2026-10-26 | 0001648257-26-000068 | | 2026-10-21 | 06:03 ET | [6-K](/filings/0001648257-26-000066.md) | Report of a foreign private issuer, period 2026-10-21 | 0001648257-26-000066 | | 2026-09-29 | 06:03 ET | [6-K](/filings/0001648257-26-000064.md) | Report of a foreign private issuer, period 2026-09-29 | 0001648257-26-000064 | | 2026-09-29 | 21:26 ET | [6-K](/filings/0001648257-26-000061.md) | Report of a foreign private issuer, period 2026-09-28 | 0001648257-26-000061 | | 2026-09-24 | 06:18 ET | [6-K](/filings/0001648257-26-000059.md) | Report of a foreign private issuer, period 2026-09-24 | 0001648257-26-000059 | | 2026-09-03 | 06:04 ET | [6-K](/filings/0001648257-26-000057.md) | Report of a foreign private issuer, period 2026-09-03 | 0001648257-26-000057 | | 2026-08-31 | 06:03 ET | [6-K](/filings/0001648257-26-000055.md) | Report of a foreign private issuer, period 2026-08-31 | 0001648257-26-000055 | | 2026-08-28 | 06:21 ET | [6-K](/filings/0001648257-26-000053.md) | Report of a foreign private issuer, period 2026-08-28 | 0001648257-26-000053 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-023822.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1648257 - Tickers: HCM, HMDCF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: E9 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:09 ET. No prices; not investment advice.